Perspectives for Clinical Translation of Adipose Stromal/Stem Cells
Adipose stromal/stem cells (ASCs) are an ideal cell type for regenerative medicine applications, as they can easily be harvested from adipose tissue in large quantities. ASCs have excellent proliferation, differentiation, and immunoregulatory capacities that have been demonstrated in numerous studie...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2019/5858247 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551162275954688 |
|---|---|
| author | Mimmi Patrikoski Bettina Mannerström Susanna Miettinen |
| author_facet | Mimmi Patrikoski Bettina Mannerström Susanna Miettinen |
| author_sort | Mimmi Patrikoski |
| collection | DOAJ |
| description | Adipose stromal/stem cells (ASCs) are an ideal cell type for regenerative medicine applications, as they can easily be harvested from adipose tissue in large quantities. ASCs have excellent proliferation, differentiation, and immunoregulatory capacities that have been demonstrated in numerous studies. Great interest and investment have been placed in efforts to exploit the allogeneic use and immunomodulatory and anti-inflammatory effects of ASCs. However, bridging the gap between in vitro and in vivo studies and moving into clinical practice remain a challenge. For the clinical translation of ASCs, several issues must be considered, including how to characterise such a heterogenic cell population and how to ensure their safety and efficacy. This review explores the different phases of in vitro and preclinical ASC characterisation and describes the development of appropriate potency assays. In addition, good manufacturing practice requirements are discussed, and cell-based medicinal products holding marketing authorisation in the European Union are reviewed. Moreover, the current status of clinical trials applying ASCs and the patent landscape in the field of ASC research are presented. Overall, this review highlights the applicability of ASCs for clinical cell therapies and discusses their potential. |
| format | Article |
| id | doaj-art-0a20024d800c4470899eee0ff3143d02 |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-0a20024d800c4470899eee0ff3143d022025-02-03T06:04:43ZengWileyStem Cells International1687-966X1687-96782019-01-01201910.1155/2019/58582475858247Perspectives for Clinical Translation of Adipose Stromal/Stem CellsMimmi Patrikoski0Bettina Mannerström1Susanna Miettinen2Adult Stem Cell Group, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, FinlandAdult Stem Cell Group, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, FinlandAdult Stem Cell Group, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, FinlandAdipose stromal/stem cells (ASCs) are an ideal cell type for regenerative medicine applications, as they can easily be harvested from adipose tissue in large quantities. ASCs have excellent proliferation, differentiation, and immunoregulatory capacities that have been demonstrated in numerous studies. Great interest and investment have been placed in efforts to exploit the allogeneic use and immunomodulatory and anti-inflammatory effects of ASCs. However, bridging the gap between in vitro and in vivo studies and moving into clinical practice remain a challenge. For the clinical translation of ASCs, several issues must be considered, including how to characterise such a heterogenic cell population and how to ensure their safety and efficacy. This review explores the different phases of in vitro and preclinical ASC characterisation and describes the development of appropriate potency assays. In addition, good manufacturing practice requirements are discussed, and cell-based medicinal products holding marketing authorisation in the European Union are reviewed. Moreover, the current status of clinical trials applying ASCs and the patent landscape in the field of ASC research are presented. Overall, this review highlights the applicability of ASCs for clinical cell therapies and discusses their potential.http://dx.doi.org/10.1155/2019/5858247 |
| spellingShingle | Mimmi Patrikoski Bettina Mannerström Susanna Miettinen Perspectives for Clinical Translation of Adipose Stromal/Stem Cells Stem Cells International |
| title | Perspectives for Clinical Translation of Adipose Stromal/Stem Cells |
| title_full | Perspectives for Clinical Translation of Adipose Stromal/Stem Cells |
| title_fullStr | Perspectives for Clinical Translation of Adipose Stromal/Stem Cells |
| title_full_unstemmed | Perspectives for Clinical Translation of Adipose Stromal/Stem Cells |
| title_short | Perspectives for Clinical Translation of Adipose Stromal/Stem Cells |
| title_sort | perspectives for clinical translation of adipose stromal stem cells |
| url | http://dx.doi.org/10.1155/2019/5858247 |
| work_keys_str_mv | AT mimmipatrikoski perspectivesforclinicaltranslationofadiposestromalstemcells AT bettinamannerstrom perspectivesforclinicaltranslationofadiposestromalstemcells AT susannamiettinen perspectivesforclinicaltranslationofadiposestromalstemcells |